SY
SYNC.LSE Syncona Limited
- Market cap
- GBX 742M
- P/E
- -
- P/B
- 0.73x
- ROE
- -0.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is SYNC.LSE undervalued?
Graham numberThe Graham number of Syncona Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Syncona Limited fundamental analysis
No fundamental analysis for Syncona Limited yet.
Syncona Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Syncona Limited
Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long ter…
Full company profileSyncona Limited financial statements
Syncona Limited annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 83.2M | 196M | 439M | -167M | 78.5M | 18.7M | -39.8M | 30.7M | -68.3M | 57.3M |
| Gross Profit | 80.3M | 189M | 413M | -175M | 78.5M | 3.68M | -51.9M | 14.1M | -68.3M | 43.4M |
| Operating Income | 82.0M | 181M | 416M | -191M | 57.9M | 13.1M | -51.4M | 8.14M | -143M | -6.83M |
| EBITDA | 82.0M | 181M | 429M | -1.91M | 57.9M | 11.1M | -4.63M | 8.14M | -143M | -8.81M |
| Net Income | 77.3M | 173M | 411M | -196M | 53.2M | 8.84M | -56.0M | 3.79M | -143M | -8.81M |
| EPS | 0.17 | 0.26 | 0.61 | -0.30 | 0.08 | 0.01 | -0.08 | 0.01 | -0.22 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 901M | 1.07B | 1.48B | 1.28B | 1.34B | 1.33B | 1.27B | 1.25B | 1.06B | 1.05B |
| Total Liabilities | 6.11M | 15.2M | 23.9M | 30.3M | 38.1M | 23.5M | 13.8M | 12.2M | 11.8M | 15.0M |
| Shareholders' Equity | 895M | 1.06B | 1.46B | 1.25B | 1.30B | 1.31B | 1.25B | 1.24B | 1.05B | 1.04B |
| Cash & Short-term Investments | 105K | 981K | 91.0K | 17.0K | 14.0K | 276K | 11.0K | 261K | 1.11M | 1.92M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 7.12M | 8.19M | 300K | 13.2M | -3.00K | 262K | -265K | 20.5M | 43.9M | 23.3M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.9M | 23.3M |
| Free Cash Flow | 7.12M | 8.19M | 300K | 13.2M | -3.00K | 262K | -265K | 20.5M | 43.9M | 23.3M |
| Ratios | ||||||||||
| ROE | 8.6% | 16.4% | 28.3% | -15.7% | 4.1% | 0.7% | -4.5% | 0.3% | -13.6% | -0.8% |
| ROA | 8.6% | 16.1% | 27.8% | -15.3% | 4.0% | 0.7% | -4.4% | 0.3% | -13.4% | -0.8% |
| Net Profit Margin | 92.9% | 88.0% | 93.7% | - | 67.7% | 47.3% | - | 12.3% | - | -15.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Syncona Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 20, 2019
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | GBP 13.2M | 0.02 | 24.9% |
| 2020 | GBP 13.2M | 0.02 | - |
| 2019 | GBP 12.2M | 0.02 | 3.0% |
| 2018 | GBP 12.5M | 0.02 | 7.2% |
| 2017 | GBP 6.66M | 0.01 | 8.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Syncona Limited
- Insiders 1.21%
- Institutions 62.89%
- Public & others 35.90%
- Shares outstanding 608M
- Free float 477M
Syncona Limited company profile
- Company name
- Syncona Limited
- Ticker
- SYNC.LSE
- ISIN
- GG00B8P59C08
- Exchange
- London Exchange
- Sector
- Financial Services
- Industry
- Capital Markets
- Employees
- 1,226
- Fiscal year end
- March
- Address
- Victoria House, London, United Kingdom, WC1B 4DA
- Phone
- 44 20 3981 7909
- Website
- synconaltd.com
About Syncona Limited
Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
Syncona Limited management
9- Mr. Kenneth H. Galbraith C.A.Chair of SIML & Executive Partner · born 1962
- Dr. Christopher J. Hollowood Ph.D.Chief Executive Officer · born 1974
- Ms. Katherine Elizabeth ButlerChief Financial officer · born 1981
- Ms. Fiona FernandezHead of Operations
- Dr. Elisa Petris Ph.D.Managing Partner
- Ms. Annabel ClarkHead of Corporate Affairs
- Mr. Roel BulthuisManaging Partner and Head of Investments · born 1976
- Dr. Samantha Roberts M.D., Ph.D.Executive Partner
- Ms. Raghd RostomPrincipal